Duration of efficacy
First year First 6 months Entire time horizon (3 years)
Quality of life
Spanish utilities 12, 13 SGRQ ( 22 ) Discount rate 3% (0% -5%)
Exacerbation unitary cost (moderate and severe)
Estimated from ( 15-17 ) ( Table 2 ) (+/-20%)
Follow-up cost according dyspnea level (3 levels)
Estimated from ( [18] [19] [20] ) (Table 2 ) (+/-20%)
Background Methods
Presented at the ISPOR 18th Annual European Congress. 7-11 November 2015, Milan, Italy. (Table 3) .
Sensitivity analysis
• In the deterministic sensitivity analysis the ICER ranged between 20,636 and 47,428 €/QALY. The parameters with the greatest impact were the modification of the utility values, the difference in efficacy between treatments and the time horizon (Figure 2 ).
• In the probabilistic sensitivity analysis the probability of UMEC/VI being cost-effective was 80.3% at a willingness-to-pay of 30,000€/QALY.
• UMEC/VI could be considered as a cost-effective treatment alternative compared with TIO in symptomatic COPD patients from the Spanish NHS perspective.
Conclusions Objectives
• The objective of this analysis was to evaluate the incremental cost-effectiveness ratio (ICER) of UMEC/VI compared with Tiotropium (TIO), from the Spanish National Health System (NHS) perspective.
Model description
• The cost-effectiveness analysis was performed using a linked equations cohort model of Chronic Obstructive Pulmonary Disease (COPD) progression based on the epidemiological longitudinal study ECLIPSE (Figure 1 ) [6] [7] [8] . A 3-year time horizon was selected and 3% discount was applied to effects and Spanish costs (expressed in €2015).
• Results were expressed using the ICER of UMEC/VI vs TIO, calculated using the formula: (Cost UMEC/VI -Cost TIO )/(QALY UMEC/VI -QALY TIO ).
• Deterministic and probabilistic sensitivity analysis (PSA) were performed. Model inputs in the base case and in the sensitivity analysis are detailed in Table 1 .
Study population and inputs
• Study population: COPD patients with a post-bronchodilator forced expiratory volume in one second (FEV1) <70% and presence of respiratory symptoms measured with the mMRC dyspnea scale (mMRC >2).
• Effectiveness: Treatment effect, expressed as FEV1 change from baseline, was estimated from a 24 week-head-to-head phase III clinical trial comparing UMEC/VI with TIO 10 and was assumed to last 52 weeks following treatment initiation (maximum duration of UMEC/VI clinical trials) 11 .
• Utilities: Spanish utility values were derived from a local observational study 12, 13 .
• Costs: Unitary costs were obtained from local sources ( 
Figure 2. Deterministic sensitivity analysis results
• Bronchodilators, such as inhaled long-acting muscarinic antagonists (LAMAs) and long-acting β 2 -agonists (LABAs), are central to the pharmacological management of stable chronic obstructive pulmonary disease (COPD). 1 -The LAMA/LABA combination of umeclidinium/vilanterol (UMEC/VI 62.5/25 mcg/day) is an approved maintenance treatment for COPD in the EU, the US and several other countries. 2,3 -The LAMA tiotropium (TIO) is also approved for the treatment of COPD. 4, 5 
